
Step Pharma develops oral drugs inhibiting CTPS1, with dencatistat in clinical trials for blood cancers.
step-ph.comCrawled Nov 9, 2026
Dencatistat is being studied as a novel therapy for individuals living with ET who have not responded to or experienced side effects from currently available treatment. A Phase 2 clinical trial commenced in June 2026.
Philip Beer, Chief Scientific Officer at Step Pharma, who is also the Chair of the Genomics Working Group of the British In Vitro Diagnostics Association (BIVDA), provides his perspectives on the recently published report titled “Leveraging partnerships to realise the UK’s potential in genomics”
Andrew took up leadership of Step Pharma in September 2019. Prior to joining Step, he was CSO at Zealand Pharma, Denmark. Prior experience, covering scientific strategy and business development, was garnered from leadership roles with Shire Pharmaceuticals, Opsona Therapeutics and AstraZeneca. He has also acquired venture capital experience as General Partner and Scientific Director for the Life Sciences Investment Fund Eclosion2.
Duc joined Step Pharma in March 2020, bringing drug development expertise across cardiovascular, anti-infective, urology, epigenetics, CNS, rare disease, and reproductive medicine. His experience includes roles at Sanofi-Aventis, Pfizer, Lundbeck, Preglem, Arisgen, EspeRare, and Prexton Therapeutics, where he advanced multiple projects into clinical development and registration.
Maureen joined Step Pharma in February 2022 after leading project management at Precision for Medicine. Previously, she directed project management at Chiltern Oncology and PRA Health Sciences, overseeing early and late-phase oncology and neurology studies.
Nicolas joined Step Pharma in October 2021 as CFO after serving at Prexton Therapeutics, which was later acquired by Lundbeck. Earlier, he was CFO of Endosense, a MedTech company acquired by St Jude Medical, and held managerial roles in Merck Serono’s controlling, forecasting, and internal audit departments.
He brings over twenty years of experience in drug discovery and drug development for big pharma companies (Sanofi-Aventis, Pfizer, Lundbeck) and biotech start-ups (Preglem, Arisgen, EspeRare, Prexton Therapeutics).
Ward has a PhD in molecular biology research and worked at VIB/UGent, the John Innes Centre and Harvard Medical School. His expertise spans both plant and animal models, and ranges from fundamental to translational research.
Step Pharma is a group of experienced executives, biotechnology entrepreneurs, and drug developers focused on accelerating the development of dencatistat for clinical use, leveraging prior experience in life-saving treatments.
By targeting CTPS1, an enzyme that catalyses a rate-limiting step in pyrimidine synthesis, Step Pharma has unlocked the ability to selectively inhibit the de novo pyrimidine synthesis pathway, enabling a highly selective treatment of cancer.
Step Pharma’s lead asset, dencatistat (STP938), is a first-in-class, orally bioavailable, targeted oncology therapy designed to integrate into multiple cancer treatment regimens.
Step Pharma presents preliminary data from its **phase 2 VECTRA trial** of **dencatistat** for treating **high-risk essential thrombocythaemia** at the **68th ASH Annual Meeting**. The oral presentation marks the first disclosure of findings from the ongoing study. Dencatistat targets disease mechanisms in this blood disorder, with results expected to provide early insights into its efficacy and safety profile.
Step Pharma appoints Neil J. Gallagher, MD, PhD, as a Non-Executive Director to support the company’s clinical development of dencatistat. Gallagher brings medical expertise to advance the drug’s programs. The appointment takes effect immediately.
Step Pharma advances its experimental drug **dencatistat** into a **phase 2 clinical trial** for treating **essential thrombocythaemia (ET)**, based on encouraging results from its prior **phase 1b trial**. The company now evaluates the drug’s safety and efficacy in a broader patient group. Dencatistat targets underlying disease mechanisms in ET, a rare blood disorder.
Step Pharma receives a €2.5 million EIC Accelerator grant to advance **dencatistat**, a treatment targeting **CTPS2 null gynaecological tumors**, including ovarian and endometrial cancers. The grant may also unlock up to €10 million in additional equity investment to support clinical development. The funding aims to accelerate progress in addressing unmet needs in these cancer types.
Step Pharma names **Dr. Karen Smith** as its new **Chief Medical Officer**, effective immediately. Smith holds advanced degrees in medicine (MD, PhD), business administration (MBA), and law (LLM) and has over **25 years of experience** in the healthcare sector. The appointment strengthens Step Pharma’s leadership in medical and regulatory strategy.
Step Pharma secures €38 million in Series C funding. The round is led by new investor V-Bio Ventures, with support from existing backers. The company continues to expand its financial backing for development efforts.
Step Pharma begins dosing the first participant in a phase 1b clinical trial testing dencatistat, a treatment for essential thrombocythaemia (ET). The open-label study assesses safety, tolerability, and early efficacy in around 20 high-risk ET patients. Researchers aim to evaluate the drug’s potential as a targeted therapy for this blood disorder.
Step Pharma secures US FDA orphan drug designation for its experimental compound **dencatistat**, targeting **T-cell lymphoma**, including peripheral and cutaneous subtypes. The designation accelerates development for rare blood cancers with limited treatment options. The company now advances clinical trials under expedited review pathways.